Immunex, Seattle, small biotechnology companies, stumbles into the highly successful and innovative product. Enbrel, tumor necrosis factor, once considered the most effective treatment for rheumatoid arthritis - $ 300 billion market in the United States. After nearly 20 years of losses, Enbrel is a savior for Immunex. But it also can be the worst nightmare of the company. Immunex, after many years of cash starved, had not been able to build production capacity to meet the sudden and massive demand for their drugs. "Hide
by Alicia Loffler, P. Geetha Krishnan MD Source: Kellogg School Management 20 pages. Publication Date: January 1, 2004. Prod. #: KEL069-PDF-ENG
Related Case Solutions & Analyses:
Crescent Standard Investment Bank Limited – Governance Failure
Wal-Mart Tries on Cheap Chic
ING Insurance AsiaPacific
Zimmer: The Gender-Specific Knee
Note on Customer Management
Using Aggregate Project Planning to Link Strategy Innovation and the Resource Allocation Process
Strategic Outsourcing
Negotiating with Romans–Part 2
CML Group Inc.: Going Public (A)
Psychology of Waiting Lines
